Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia
NCT ID: NCT02618109
Last Updated: 2022-10-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE4
119 participants
INTERVENTIONAL
2016-01-31
2022-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma
NCT01766583
Treatment of Mature B-cell Lymphoma/Leukaemia
NCT00162656
Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
NCT01466868
Relmacabtagene Autoleucel in Patients With LBCL
NCT06142175
Lenalidomide in Relapsed or Refractory Primary-cutaneous Large B-cell Lymphoma Leg-type : Multicentre Prospective Phase II Single Arm Trial of the French Study Group of Cutaneous Lymphoma
NCT01556035
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Relapse Group
* Collection of blood samples will be done in newly diagnosed relapse of B-ALL children at the time of relapse diagnosis.
* Children aged from 1 to 18 years at the time of first B-ALL relapse diagnosis.
Collection of blood samples
Collection of blood samples
Control Group
* Collection of blood samples will be done at the same stage of treatment as the relapse group has been collected.
* Children aged from 1 to 18 years enrolled into FRALLE (protocol of treatment) or EORTC (European Organisation for Research and Treatment of Cancer) treatment protocols, treated for B-ALL and who are in complete molecular remission.
* These control patients will be recruited at the same time from the beginning of B-ALL treatment as paired-relapsed control patients.
Collection of blood samples
Collection of blood samples
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Collection of blood samples
Collection of blood samples
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Obtention of oral and written consent of the parents
* Parents affiliated with the social security system
* Children aged from 1 to 18 years enrolled into FRALLE or EORTC treatment protocols, treated for B-ALL and who are in complete molecular remission
* Obtention of oral and written consent of the parents
* Parents affiliated with the social security system
Exclusion Criteria
1 Year
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Angers
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Isabelle PELLIER, PU-PH
Role: PRINCIPAL_INVESTIGATOR
UNIVERSITY HOSPITAL OF ANGERS
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital of Amiens
Amiens, , France
University Hospital of Angers
Angers, , France
University Hospital of Besancon
Besançon, , France
University Hospital of Bordeaux
Bordeaux, , France
University Hospital of Caen
Caen, , France
Civil Hospices of Lyon
Lyon, , France
University Hospital of Marseille
Marseille, , France
University Hospital of Nancy
Nancy, , France
University Hospital of Nantes
Nantes, , France
University Hospital of Nice
Nice, , France
University Hospital of Trousseau (Paris)
Paris, , France
University Hospital of Robert Debre (Paris)
Paris, , France
University Hospital of Reims
Reims, , France
University Hospital of Rennes
Rennes, , France
University Hospital of Saint Etienne
Saint-Etienne, , France
University Hospital of Strasbourg
Strasbourg, , France
University Hospital of Toulouse
Toulouse, , France
University Hospital of Tours
Tours, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2015-A00621-48
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.